Life Science News

  • Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a "patent ductus arteriosus" (PDA) in newborns
  • Study found low adverse event rates following a Piccolo procedure, showing additional benefit of the device that can help babies avoid riskier surgery
  • A PDA is present in approximately 1 in 2,000 births 1

Abbott (NYSE: ABT) today announced three-year data showing the positive impact of the Amplatzer Piccolo™ Occluder on treating babies (some weighing as little as two pounds) with a potentially life-threatening hole in the heart known as a patent ductus arteriosus (PDA). The Amplatzer Piccolo device is smaller than a pea and is the world's first and only minimally invasive, transcatheter treatment approved to close a PDA in premature infants with this common congenital heart defect.

The latest data were presented at the Pediatric and Congenital Interventional Cardiovascular Society Symposium, held in Chicago from September 7-10, 2022 .

A PDA is an opening between two blood vessels in an infant's heart that fails to close as it should following birth. Before a baby is born, this channel allows blood to bypass the not-yet-functioning lungs because the fetus gets oxygen-rich blood from the mother. If the hole remains open after birth, it changes the flow pattern so additional blood is directed to the lungs, making it difficult for babies to breathe normally. Prior to the development of Abbott's minimally invasive Piccolo closure device, physicians and families often had to decide between placing a baby on respiratory support to see if the defect sealed on its own or conducting a risky surgical procedure to close the PDA.

Three-Year Results from the Amplatzer Piccolo Study

The ADO II AS trial showed the safety and effectiveness of the Amplatzer Piccolo device in closing PDAs in premature babies, with data through three years showing:

  • High survival rate (95.5%), with no procedure-related deaths
  • High implant success rate (95.5%) and complete PDA closure in nearly all patients
  • Low device-related serious adverse event rate (2%) with no late (>1 year) device-related events

The data confirm that the Amplatzer Piccolo Occluder can offer high success rates in terms of PDA closure while offering low adverse event rates. The minimally invasive approach to delivery of the device also reduces the need to subject many of the tiniest patients to riskier surgical procedures.

"The Amplatzer Piccolo Occluder is a lifesaving device for premature infants with PDAs, many of whom require urgent treatment to survive but aren't responding to medical management and are at high risk for surgery," said Evan Zahn , M.D., director of the Guerin Family Congenital Heart Program in the Smidt Heart Institute and Department of Pediatrics at Cedars-Sinai Medical Center, and principal investigator of the ADO II AS trial. "The data from this study reinforce Piccolo's ability to safely and effectively treat this life-threatening heart problem for our tiniest patients."

About the Amplatzer Piccolo Occluder

The Amplatzer Piccolo is a self-expanding, wire mesh device that is inserted through a small incision in the leg and guided through vessels to the heart, where it's placed to seal the PDA. As a minimally invasive procedure, many of the premature babies who are critically ill in the neonatal intensive care unit can be weaned from artificial respirator support soon after the device is implanted. The U.S. Food and Drug Administration approved the Amplatzer Piccolo Occluder in 2019.

Almost seven years ago, "Little Tony" Daly of Las Vegas was the first to receive the Amplatzer Piccolo as an investigational device. Born at 26 weeks and weighing about two pounds, Tony had a PDA that caused fatigue and intestinal issues.

"We trusted the doctor's recommendation to close Tony's PDA with Abbott's Amplatzer Piccolo Occluder, and we're thankful we did – we consider the device to be our son's lifesaver," said Anthony Daly , Tony's father. "There was an immediate improvement in Tony's health just days after the procedure and today he's a thriving first grader who's active in soccer, tennis and hockey."

"There are thousands of stories of infants in need that inspire us to continue innovating to help the youngest and most vulnerable babies," said Michael Dale , senior vice president of Abbott's structural heart business. "We realize just how important our commitment to restoring health is when we hear about pediatric patients who can begin living their best lives thanks to devices like our Amplatzer Piccolo Occluder."

Abbott's portfolio of pediatric heart therapies also includes the world's smallest rotatable mechanical heart valve, the Masters HP 15mm, and the HeartMate 3 heart pump which is approved for pediatric patients. Abbott is committed to developing lifesaving pediatric devices that have an immediate impact with long-term benefits, reduce the risks of life-threatening complications and allow physicians to confidently treat the youngest and tiniest patients.

For U.S. Important Safety Information about the Amplatzer Piccolo Occluder, visit https://abbo.tt/PiccoloISI .

For U.S. Important Safety Information about the Masters HP 15mm valve, visit https://abbo.tt/MastersISI .

For U.S. Important Safety Information about the HeartMate 3, visit https://cardiovascular.abbott/hm3isw .

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

1 Krasuki, R. A. (2006). Patent ductus arteriosus closure. Journal of Interventional Cardiology, 19 (5 Suppl), S60-S66.

Cision View original content: https://www.prnewswire.com/news-releases/three-year-data-on-worlds-smallest-heart-device-show-benefits-of-fixing-holes-in-newborn-hearts-without-surgery-301620348.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

Keep reading...Show less
abt stock

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 "long haulers," who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

Cyclacel Reports Fourth Quarter And 2016 Financial Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its financial results for the fourth quarter and full year 2016.
As quoted in the press release:

The Company’s net loss applicable to common shareholders for the three months and year ended December 31, 2016 was $2.9 million and $12.0 million, respectively. As of December 31, 2016, cash and cash equivalents totaled $16.5 million.

Keep reading...Show less
ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Inc. ("ALRT") (OTCQB: ALRT), the diabetes management company, is pleased to announce an update with respect to its migration to Singapore. Further to its Form 8-K filed May 20, 2022, and press release issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. ("ALRT Singapore"), has been declared effective by the Securities and Exchange Commission (the "SEC"). ALRT anticipates mailing the corresponding prospectus and information statement to its stockholders on or around October 4, 2022. ALRT expects to consummate the previously announced reincorporation merger in which ALRT will become a wholly owned subsidiary of ALRT Singapore as soon as practicable following the required 20-day waiting period subsequent to mailing of the prospectus and information statement, subject to the satisfaction of customary closing conditions, including certain regulatory approvals from FINRA, the OTC Markets Group, ACRA (Singapore), and the Secretaries of State of Nevada and Delaware.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Source Half of its U.S. Electricity Needs from Wind Power Purchase with Enel North America

The agreement will deliver renewable energy equal to half of the company's U.S. electricity consumption

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, recently signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma. Thermo Fisher will purchase approximately 400,000 megawatt hours (MWh) of renewable electricity, equal to half of the company's current U.S. electricity needs.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
6 Small Medical Device Companies (Updated 2022)

6 Small Medical Device Companies (Updated 2022)

The medical device sector in Canada may be one of the country’s best-kept global secrets.

According to the Canadian government, the nation has a large number of medical device manufacturers working to advance product innovation. Data from 2020, the most recent period available, shows that the country brought US$7.5 billion to the medical device sector that year, which is 1.8 percent of the worldwide market.

Medical devices include items like pacemakers, artificial heart valves, diagnostic and imaging equipment, in vitro diagnostics, dialysis equipment, hip and knee implants, synthetic skin, surgical tools, orthopedics, medical imaging and infusion pumps.

Keep reading...Show less

Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Bausch Health Companies Inc. (NYSETSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exchange Offers, the "Offers") to amend certain provisions of the indentures (the "Proposed Amendments") with respect to the respective applicable series of Existing Senior Notes. The terms and conditions of the offers and consent solicitations are described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated August 30, 2022 (the "Exchange Offer Memorandum").

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company

Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand

Johnson & Johnson (the "Company") (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or "the Company") is pleased to announce it placed No. 22 on the 2022 Report on Business ranking of Canada's Top Growing Companies.

Canada's Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 1,850%.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×